Actively Recruiting

Phase Not Applicable
Age: 50Years - 69Years
All Genders
Healthy Volunteers
NCT06703632

Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection

Led by ADVANCED MARKER DISCOVERY S.L. · Updated on 2025-02-27

4538

Participants Needed

2

Research Sites

45 weeks

Total Duration

On this page

Sponsors

A

ADVANCED MARKER DISCOVERY S.L.

Lead Sponsor

H

Hospital Universitario Ramon y Cajal

Collaborating Sponsor

AI-Summary

What this Trial Is About

The objective of this low-risk interventional study is to evaluate whether the PreveCol® test has sufficient efficiency to be considered as a second-line method for the detection of both colorectal cancer and advanced adenomas when used prospectively in the screening population with a previous positive FOBT result, which could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to be answered are: * Values of efficacy, efficiency, impact and safety of PreveCol. * Values of preferences of participants for screening methods. * Values of PREMs into screening programme. Participants will provide a blood sample prior to a screening colonoscopy, and complete two questionnaires. They will give their sample, information and clinical data to the investigator or health care personnel.

CONDITIONS

Official Title

Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection

Who Can Participate

Age: 50Years - 69Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 50 and 69 years at time of consent
  • Signed informed consent after understanding the study
  • Positive result from FIT/FOBT test and referred for colonoscopy
  • Asymptomatic with average risk for colorectal cancer (no personal or family history of colorectal cancer, adenoma, or inflammatory bowel disease)
Not Eligible

You will not qualify if you...

  • Diagnosis of any other cancer within 5 years prior to study
  • Previous chemotherapy or radiotherapy within 5 years
  • Diagnosis of Familial Adenomatous Polyposis, Lynch Syndrome, or Inflammatory Bowel Disease
  • Inadequate bowel preparation for colonoscopy (BBPS score ≤1 in any colon section, except colorectal cancer diagnosis)
  • Polypectomy performed in the previous 5 years
  • Hemolysis or absence of blood sample
  • Being detained by judicial or official request
  • Dependent personal or non-medical relationship with the sponsor or investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Hospital de Santa Maria

Lisbon, Lisbon District, Portugal

Not Yet Recruiting

2

Hospital Universitario Ramon y Cajal

Madrid, Madrid, Spain

Actively Recruiting

Loading map...

Research Team

M

Marta Jimenez, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

SCREENING

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection | DecenTrialz